Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.

Studied

A review assessed semaglutide and tirzepatide research in metabolic fatty liver disease and its inflammatory form, MASH.

Who / model

The review covers phase 2 and interim phase 3 clinical evidence. The abstract gives no pooled participant count or follow-up duration.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Phase 2 studies showed improved liver inflammation, with encouraging scar-tissue findings for tirzepatide. Interim phase 3 semaglutide data showed MASH resolution and reduced fibrosis. The abstract gives no numerical effect sizes.

Limits

Long-term studies are still needed to establish durability, safety and effects on major liver-related clinical outcomes.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary